布马佐辛 | 75684-07-0

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 6,7-苯并吗啡烷
• 中文名称: 布马佐辛
• 英文名称: Bremazocine
• 英文别名: (1S,9R)-1-ethyl-10-[(1-hydroxycyclopropyl)methyl]-13,13-dimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
• CAS: 75684-07-0
• 化学式: C₂₀H₂₉NO₂
• 分子量: 315.4
• InChiKey: ZDXGFIXMPOUDFF-XLIONFOSSA-N

物化性质

• 沸点：
  451.2±45.0 °C(Predicted)
• 密度：
  1.155±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  43.7
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] N-OXIDES OF 4,5-EPOXY-MORPHINANIUM ANALOGS<br/>[FR] N-OXYDES D'ANALOGUES 4,5-ÉPOXY-MORPHINANIUM
  申请人：PROGENICS PHARM INC

  公开号：WO2009067275A1

  公开（公告）日：2009-05-28

  Novel N-oxides of 4,5-epoxy-morphinanIum analogs are disclosed. Pharmaceutical compositions containing the N-oxides of 4,5-epoxy-morphinanium analogs and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as modulators of opioid receptors.

  揭示了4,5-环氧吗啡啉盐类的新型N-氧化物。还揭示了含有4,5-环氧吗啡啉盐类的N-氧化物的药物组合物，以及它们的药用方法。所揭示的化合物可用作阿片受体调节剂等用途。
• Combination of benzyl-4, 5-dihydro-1H-imidazole derivative and an opioid receptor ligand
  申请人：Laboratorios del Dr. Esteve S.A.

  公开号：EP2014288A1

  公开（公告）日：2009-01-14

  The present invention refers to a combination of a Compound A, a benzyl-4,5-dihydro-1 H-imidazole derivative according to formula (I) and a Compound B, an opioid receptor ligand; especially of xylometazoline or oxymetazoline and a µ-opioid receptor agonist, most preferably of xylometazoline or oxymetazoline and morphine; a medicament comprising this combination; a pharmaceutical formulation for nasal application comprising this combination; or the use of this combination for the treatment of the symptoms of pain, or the prevention or the prophylaxis of the symptoms of pain, whereas pain particularily encompasses visceral pain, chronic pain, cancer pain, acute pain or neuropathic pain, specifically involving also breakthrough pain.

  本发明涉及一种化合物A，即按照式(I)的苄基-4,5-二氢-1H-咪唑衍生物和一种化合物B，一种阿片受体配体的组合；特别是甲苯鼻塞或鼻塞通或一种μ-阿片受体激动剂，最好是甲苯鼻塞或鼻塞通和吗啡；包括这种组合的药物；包括这种组合的鼻用制剂；或者使用这种组合治疗疼痛症状，或者预防或预防疼痛症状，其中疼痛特别包括内脏疼痛、慢性疼痛、癌症疼痛、急性疼痛或神经病理性疼痛，特别还涉及突破性疼痛。
• [EN] POLYPEPTIDE-OPIOID CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS POLYPEPTIDES OPIOÏDES ET UTILISATIONS ASSOCIÉES
  申请人：ANGIOCHEM INC

  公开号：WO2013056096A1

  公开（公告）日：2013-04-18

  The invention features polypeptide-opioid conjugates capable of crossing the blood-brain barrier. The polypeptide-opioid conjugates can be used to treat a condition that is modulated by opioid receptors such as pain (e.g., postoperative pain, cancer pain, acute pain, and chronic pain).

  这项发明涉及能够穿越血脑屏障的多肽-阿片类肽共轭物。这些多肽-阿片类肽共轭物可用于治疗受阿片类受体调节的疾病，如疼痛（例如术后疼痛、癌症疼痛、急性疼痛和慢性疼痛）。
• Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase
  申请人：——

  公开号：US20020119964A1

  公开（公告）日：2002-08-29

  Homoiminopiperidinyl Hexanoic Acid derivatives and pharmaceutically acceptable salts thereof useful in the inhibition of the inducible isoform of nitric oxide synthase are disclosed.

  本发明涉及用于抑制诱导型一氧化氮合酶的Homoiminopiperidinyl Hexanoic Acid衍生物及其药用盐。
• Combination of a 5-HT7 receptor ligand and an opioid receptor ligand
  申请人：Laboratorios del Dr. Esteve S.A.

  公开号：EP1997493A1

  公开（公告）日：2008-12-03

  The present invention refers to a combination of a 5HT7 receptor ligand and an opioid recptor ligand, especially of a 5HT7 receptor agonist and an opioid recptor agonist, a medicament comprising this combination, or the use of this combination for the treatment of the symptoms of pain, the prevention or the prophylaxis of the symptoms of pain.

  本发明涉及一种5HT7受体配体和阿片受体配体的组合，特别是一种5HT7受体激动剂和阿片受体激动剂，包含该组合的药物，或者利用该组合治疗疼痛症状，预防或预防疼痛症状的用途。